key: cord-0690812-mrznt2dx
authors: Rubin, Sébastien; Orieux, Arthur; Prevel, Renaud; Garric, Antoine; Bats, Marie-Lise; Dabernat, Sandrine; Camou, Fabrice; Guisset, Olivier; Issa, Nahema; Mourissoux, Gaelle; Dewitte, Antoine; Joannes-Boyau, Olivier; Fleureau, Catherine; Rozé, Hadrien; Carrié, Cédric; Petit, Laurent; Clouzeau, Benjamin; Sazio, Charline; Bui, Hoang-Nam; Pillet, Odile; Rigothier, Claire; Vargas, Frederic; Combe, Christian; Gruson, Didier; Boyer, Alexandre
title: Characterization of acute kidney injury in critically ill patients with severe coronavirus disease 2019
date: 2020-06-06
journal: Clin Kidney J
DOI: 10.1093/ckj/sfaa099
sha: f513e14f99dfeb964203c42b0009374c9c49908e
doc_id: 690812
cord_uid: mrznt2dx

BACKGROUND: Coronavirus disease 2019 (COVID-19)-associated acute kidney injury (AKI) frequency, severity and characterization in critically ill patients has not been reported. METHODS: Single-centre cohort performed from 3 March 2020 to 14 April 2020 in four intensive care units in Bordeaux University Hospital, France. All patients with COVID-19 and pulmonary severity criteria were included. AKI was defined using Kidney Disease: Improving Global Outcomes (KDIGO) criteria. A systematic urinary analysis was performed. The incidence, severity, clinical presentation, biological characterization (transient versus persistent AKI; proteinuria, haematuria and glycosuria) and short-term outcomes were evaluated. RESULTS: Seventy-one patients were included, with basal serum creatinine (SCr) of 69 ± 21 µmol/L. At admission, AKI was present in 8/71 (11%) patients. Median [interquartile range (IQR)] follow-up was 17 (12–23) days. AKI developed in a total of 57/71 (80%) patients, with 35% Stage 1, 35% Stage 2 and 30% Stage 3 AKI; 10/57 (18%) required renal replacement therapy (RRT). Transient AKI was present in only 4/55 (7%) patients and persistent AKI was observed in 51/55 (93%). Patients with persistent AKI developed a median (IQR) urine protein/creatinine of 82 (54–140) (mg/mmol) with an albuminuria/proteinuria ratio of 0.23 ± 20, indicating predominant tubulointerstitial injury. Only two (4%) patients had glycosuria. At Day 7 after onset of AKI, six (11%) patients remained dependent on RRT, nine (16%) had SCr >200 µmol/L and four (7%) had died. Day 7 and Day 14 renal recovery occurred in 28% and 52%, respectively. CONCLUSION: Severe COVID-19-associated AKI is frequent, persistent, severe and characterized by an almost exclusive tubulointerstitial injury without glycosuria.

Since December 2019, coronavirus disease 2019 (COVID-19) has infected nearly 5 million people worldwide, leading to more than 300 000 deaths. Starting in China, it rapidly expanded to Europe, affecting first Italy, then Spain and France. Globally, it has resulted in the confinement of nearly 3 billion people [1, 2] . The severe respiratory damages requiring prolonged intubation have already been described, which are the determinant of intensive care unit (ICU) admission and have resulted in a consecutive risk of ICU saturation [3] [4] [5] [6] .

Acute kidney injury (AKI) is the second most common organ damage in COVID-19 patients previously reported in China. It is observed in up to 15% of patients, whatever their need for ICU admission [4] . However, very few data are available in patients admitted to ICUs, where this incidence should be significantly higher. According to the first US report of ICU patients (n ¼ 24) [5] , it is observed in 20% of subjects; this does not reflect the first Western European findings, where >50% of patients could experience AKI (unpublished data). The reason for this is not clearly established. AKI severity and potential recovery have not been reported. The need for renal replacement therapy (RRT) may considerably prolong the length of ICU hospitalization, leading to significant organizational and economic challenges for health-care systems. In addition, a high frequency of AKI could result in a very significant increase in the number of patients suffering from longterm chronic kidney disease (CKD) [7] .

The hypothesis was that COVID-19-associated AKI is more severe and common than previously reported, and may be represented by different clinical presentations including transient AKI, acute tubular necrosis (ATN) or other types of injury. Each of these clinical presentations potentially requires a specific approach. The objective of the study was to describe the incidence and severity and to characterize COVID-19-associated AKI.

This cohort study was carried out in the four ICUs dedicated to severe COVID-19 patients at the University Hospital of Bordeaux, France from 3 March 2020 to 14 April 2020. Patients data were routinely collected in dedicated electronic health records during their entire hospital stay. According to French law and the French Data Protection Authority, the handling of these data for research purposes was declared to the Data Protection Officer of the University Hospital of Bordeaux. The study obtained the approval of the Institutional Review Board of the University Hospital of Bordeaux (declaration number 2020- 14) . Patients (or their relatives, if any) were notified about the anonymized use of their health care data via the department's booklet.

Patients were enrolled if they were aged !18 years, had a positive polymerase chain reaction for COVID-19 or typical computed tomography findings in patients with a high clinical pretest probability of COVID-19 [8] , and had severity criteria for admission to one of the four ICUs. These severity criteria were defined by the need for !4 L/min oxygen therapy (O 2 ) to obtain an arterial oxygen saturation (SaO 2 ) !94% or arterial partial pressure of oxygen/fraction of inspired oxygen ratio (PaO 2 /FiO 2 ) 300 mmHg in patients receiving high-flow nasal cannula oxygen. The University Hospital of Bordeaux was confronted with a far less aggressive epidemic context than those reported in other French regions or other countries. Therefore, all patients presenting with this severity were systematically admitted to ICU except those who had withdrawal orders. No specific withdrawal policy was applied during this epidemic period. ICU patients were excluded from this study only if they had pre-existing end-stage kidney disease defined by the need for RRT.

Patients were treated according to the standard of care. In three units, hydroxychloroquine (HCL) was administered because of physicians' personal decision according to physiopathological studies suggesting an in vitro efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The dosage schedule was per os 400 mg twice a day. at Day 1 and then 200 mg twice a day for 5-10 days. One unit added tocilizumab to HCL with a single 8 mg/kg infusion. Two units administered lopinavir/ritonavir (400 mg twice a day in syrup form) at first and then stopped because of drug shortage. All treatments were started on the day of admission to ICU. Importantly, no other modification in COVID-19 critically ill patients' care occurred, and treatment administration was dependent on the unit and not on patients' characteristics. All patients had Foley catheterization.

The Kidney Disease: Improving Global Outcomes (KDIGO) definition was used to define AKI Stages 1, 2 and 3 [9] . Serum creatinine (SCr) and urine output were both taken into account. Stage 1: SCr 1.5-1.9 times baseline or diuresis <0.5 mL/kg/h for 6-12 h; Stage 2: SCr 2.0-2.9 times baseline or diuresis <0.5 mL/kg/h for !12 h; Stage 3: SCr !3 times baseline, initiation of RRT, anuria !12 h or diuresis <0.3 mL/kg/h for !24 h. AKI stage was classified using the worst SCr or diuresis during the entire ICU stay.

Baseline SCr values corresponded to SCr values at admission in the case of normal renal function or SCr values from within 6 months in the case of abnormal SCr at admission. All SCr baseline values could be collected from previous medical records for patients with abnormal SCr at ICU admission.

Acute kidney disease (AKD) staging was performed using the consensus report of the Acute Disease Quality Initiative (ADQI) 16 workgroup [9] and was defined as a condition wherein criteria for AKI Stage 1 or greater persists !7 days after an exposure. AKD Stage 1: SCr 1.5-1.9 times baseline; Stage 2: SCr 2.0-2.9 times baseline, Stage 3: SCr !3 times baseline or ongoing need for RRT.

Information relative to drugs taken before admission, date and type of the first COVID-19 symptoms, and a medical history of hypertension, diabetes, chronic heart failure (chronic ischaemic, rhythmic, valvular heart disease or heart failure with preserved ejection fraction or reduced ejection fraction), stroke, chronic obstructive pulmonary disease, asthma and peripheral arterial disease was collected using prospectively recorded data, and patient or relative questioning. Pre-admission exposure to non-steroidal anti-inflammatory drugs and renin-angiotensin system inhibitors was considered if the patient had taken the drug the week prior to admission. Weight and height were measured at ICU admission. All other healthcare data were collected using Metavision ICU (iMDsoft).

The four ICUs of the University Hospital of Bordeaux received patients (n ¼ 26) transferred from the ICUs of the Metz Haguenau, Aulnay Sous Bois, Corbeil Essonnes, Mulhouse or Strasbourg Hospitals in France. They were included whenever they met the inclusion criteria of the ICU admission cohort. Health-care data were collected using medical records from the previous hospital. Patients chronically exposed to immunosuppressive drugs or suffering from haematologic malignancies were considered immunosuppressed.

CKD was defined as an estimated glomerular filtration rate of <60 mL/min/1.73 m 2 , using the Chronic Kidney Disease Epidemiology Collaboration corresponding to CKD Stage 3 or more according to the KDIGO classification [9] .

Fluid balance was the addition of fluid infusion volume, including enteral or parenteral nutrition minus diuresis and gastrointestinal losses.

Minimum diuresis was defined by the minimum diuresis/kg/ h used for the KDIGO classification.

All blood or urine biological assessments were usually standardized in ICUs participating in the study and systematically collected. All biochemical parameters were determined on Abbot Architect analysers with enzymatic method for creatinine and colorimetric bromocresol purple method for albumin. SCr was measured at least once a day. A urinary analysis was performed at ICU admission or whenever AKI occurred or deteriorated during the ICU stay. Fractional excretion of sodium (FeNa þ ) and fractional excretion of urea (FeUrea) were calculated as follows: FeNa þ (%) ¼ ([U/P sodium]/[U/P creatinine]) Â 100; FeUrea (%) ¼ ([U/P urea]/[U/P creatinine]) Â 100. U/P is urinary/plasma ratio, and urinary osmolarity was measured. severe COVID-19-associated AKI | 3

The AKI day was the first day during which the patient was eligible for AKI using KDIGO classification.

Since 2017, RRT initiation criteria have been standardized in the ICUs participating in the study, according to the delayed strategy of the Artificial Kidney Initiation in Kidney Injury (AKIKI) trial [10] . Patients were eligible for RRT whenever AKI Stage 3 occurred with clinical indications (anuria !72 h, [K þ ] >6 mmol/L or >5.5 mmol/L after medical correction, acute pulmonary oedema, pH <7.15 in the absence of other causes, or blood urea >40 mmol/L).

The ICU length of stay was only calculated for patients who were discharged from the ICU; most of them were transferred to medical wards or a continuing care unit.

The intubation length was only calculated for the subgroup of patients who were successfully extubated. If a patient ever needed to be re-intubated after having been weaned from the ventilator, the intubation length was calculated as the sum of the different periods during which invasive mechanical ventilation was required.

Transient AKI was defined by a !50% decrease in SCr or a return of SCr to its baseline value 72 h after AKI [11] .

Recovery from AKI was defined as a return of SCr to 125% above baseline SCr for alive and non-dependent RRT patients during the ICU stay [12] .

Major adverse kidney events (MAKEs) was a composite outcome defined by an SCr >200% of baseline, need for RRT or death [13] .

Statistical analysis was carried out using JMP V R Version 14 (SAS Institute Inc., Cary, NC, USA, 1989-2007). Descriptive statistics included mean 6 standard deviation (SD) or median [interquartile range (IQR)] if the variable did not fit a normal distribution. Quantitative variables were compared using a t-test, and qualitative variables were compared using Fisher's exact test when only two variables were studied; Pearson's Chi-squared test was used for more variables. AKI incidence during ICU hospitalization and renal recovery during hospitalization was plotted using a Kaplan-Meier curve with a 95% confidence interval, and was censored with death. A value of double-sided P < 0.05 was considered statistically significant.

March 2020, 380 patients were admitted in the University Hospital of Bordeaux for COVID-19. Among them, 45/ 380 (12%) patients with severe COVID-19 were admitted to the ICU in addition to 26 critically ill patients admitted to ICU from other regions of France, for a total of 71 patients included (Figure 1 ). The reason for admission was acute respiratory failure for 70/71 (99%), with a majority of males-55/71 (77%)-and a mean age of 61 6 12 years. Time from the onset of first viral symptoms to ICU admission was 8 (6-10) days. Details on all baseline characteristics, including blood test results at admission, are presented in Table 1 .

Median follow-up was 17 (12-23) days, and length of ICU stay was 10 (7-14) days. Intubation was required for 55/71 (77%) patients for a median duration of 12 (9) (10) (11) (12) (13) (14) (15) (16) (17) days. The worst PaO 2 /FiO 2 was 95 (79-125). Septic shock was rare since norepinephrine infusion rate [maximum 0.16 (0.10-0.37) mg/kg/min] was low and no lactate level exceeded 2 mmol/L except in two patients [14] . Four patients died (11%). Table 2 shows the main follow-up outcomes. (13) Table 3 . (Table 4) .

Patients with persistent AKI developed a median proteinuria/creatininuria of 82 (54-140) mg/mmol with an albuminuria/ proteinuria ratio of 0.13 (0.07-0.32). Haematuria was present in 35/51 (69%) patients; leucocyturia was present in 24/51 (47%) patients. Glycosuria was found in 2/51 (4%) patients.

At Day 7 after AKI, 6/57 (11%) patients remained dependent on RRT, 9/57 (16%) had SCr >200 mmol/L and 4/57 (7%) died, accounting for 19/57 (33%) patients reaching MAKE criteria. Renal recovery occurred in 28% of patients at Day 7, 52% at Day 14 and 64% at Day 21 ( Figure 2B ).

In this study, the incidence of COVID-19-associated AKI was higher (80%) than reported previously (3-20%) [4, 6, 15] . Cases were severe, with 30% Stage 3 and 18% RRT and not transient; >90% of cases were persistent AKI. The value of urinary indices to differentiate transient versus persistent AKI in this context might be questioned. Both high proteinuria and low albuminuria were not in favour of a prevalent glomerular injury and suggest acute tubular injury (ATI), interstitial nephritis (IN) or both. The very low incidence of glycosuria was not in favour of Fanconi syndrome. Haematuria and leucocyturia could not be interpreted by the presence of foley catheter for all patients.

To the best of our knowledge, this is the first study to systematically explore COVID-19-associated AKI, particularly in more severe patients. The higher incidence of AKI observed in this study can be explained in different ways. First, it could be related to the severity of the disease by an increase in the initial renal viral charge and/or severe systemic inflammation. Moreover, the exhaustive collection of basal SCr of ICU patients could contribute to this higher incidence, providing a more realistic spectrum of COVID-19-associated renal injury.

Whether the cause of AKI is ATI, IN or both is debatable. ATN, the most common form of ATI, is mainly influenced by haemodynamic parameters and iodinated contrast agents [16] . In this study, the use of these agents was limited (20%). The haemodynamic instability of patients with AKI was slight due to high sedation infusion rate [17] . No septic shock was observed and no differences in inflammatory states (C-reactive protein and ferritin) were observed between AKI and non-AKI patients. This suggests the possibility of a viral-specific ATI. SARS-CoV-2 (the virus causing COVID-19) penetrates the cells via two receptors [Angiotensin-converting enzyme 2 (ACE2) and Transmembrane protease, serine 2 (TMPRSS2)] [18] . While ACE2 is highly expressed in proximal tubular epithelial cells and in podocytes, TMPRSS2 is only detectable in the proximal tubule S3 segment. By infiltrating the renal tubular cell, SARS-CoV-2 might induce ATI. This could explain why 9 out of 26 autopsied patients in China with COVID-19-associated AKI had primarily diffused proximal tubular injury, with some frank necrosis and no glomerular injury [19] . Another post mortem study showed severe ATI with IN (CD68þ macrophage infiltration of the tubulointerstitium) [20] . However, in these post mortem studies, patients had less severe renal involvement and may not be representative of more severe patients. Pulmonary damages have been reported as an inflammatory pattern integrated into a cytokine storm syndrome [21] . The frequent association we report between renal and pulmonary injuries might have several explanations. First, co-occurrence does not necessarily mean a common pathway. However, one is left to wonder if infection with SARS-CoV-2 may result in inflammation or direct viral injury of both organs. Renal biopsies in patients with severe COVID-19-associated AKI might thus be considered and The length of intubation was only calculated for patients who were successfully weaned from the ventilator, n ¼ 29.

FiO2, fraction of inspired oxygen; ICU, intensive care unit; NE, norepinephrine;

PaO2, arterial partial pressure of oxygen.

severe COVID-19-associated AKI | 5 lead to specific anti-inflammatory therapies for INpredominant AKI. While FeUrea and FeNaþ have been previously reported as relevant for the differentiation of transient AKI from persistent AKI [11, 22] , this was not shown in the current study.

Limitations of our work include the small number of patients (n ¼ 71) and a limited median follow-up period (2 weeks). These results will have to be confirmed by larger studies with longer follow-up period.

In conclusion, this study should make physicians aware of the likely existence of a frequent, severe and specific COVID-19associated AKI. The study provides additional insights into the characterization of AKI: a tubulointerstitial injury without glycosuria. Further work should be carried out promptly in order to identify and assess specific therapeutic options. (21) BMI, body mass index; FiO2, fraction of inspired oxygen; MAP, mean arterial pressure; NE, norepinephrine; PaO2, arterial partial pressure of oxygen; SAPS, simplified acute physiology score.

severe COVID-19-associated AKI | 7

Clinical characteristics of coronavirus disease 2019 in China

Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Covid-19 in critically ill patients in the Seattle Region-case series

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region

The incidence of chronic kidney disease three years after non-severe acute kidney injury in critically ill patients: a single-center cohort study

Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases

Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup

Initiation strategies for renal-replacement therapy in the intensive care unit

Diagnostic performance of fractional excretion of urea in the evaluation of critically ill patients with acute kidney injury: a multicenter cohort study

Klarenbach S; for the Alberta Kidney Disease Network. Association between AKI, recovery of renal function, and long-term outcomes after hospital discharge

Clinical trial endpoints in acute kidney injury

The third international consensus definitions for sepsis and septic shock (sepsis-3)

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State

Diagnostic work-up and specific causes of acute kidney injury

Neurologic features in severe SARS-CoV-2 infection

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China

Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv.org

COVID-19: consider cytokine storm syndromes and immunosuppression

Fractional excretion of urea as a diagnostic index in acute kidney injury in intensive care patients

Table 4. Comparison between patients with transient versus persistent AKI

We would like to thank the subjects and the clinical and clerical teams involved in this study. We also thank Philippe 

No funding disclosures. 15 2/10 (20) Acute pulmonary oedema 0 (0) Death, n (%) 0 (0) 2/51 (4) 1 Fe, fractional excretion; K þ , potassium; Na þ , sodium; NA, not available; NR, not relevant; UNa þ /K þ ratio, urinary sodium/potassium ratio.